Letaplimab represents a distinct medical method for managing complement-mediated illnesses. This monoclonal antibody targets C1q, a essential factor of the complement system, potentially inhibit its initial https://oisihdsl668826.blogdigy.com/letaplimab-a-new-therapeutic-approach-65321163